Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Advances in the delivery of buprenorphine for opioid dependence.

Rosenthal RN, Goradia VV.

Drug Des Devel Ther. 2017 Aug 28;11:2493-2505. doi: 10.2147/DDDT.S72543. eCollection 2017. Review.

2.
3.

Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria.

Dennis BB, Roshanov PS, Naji L, Bawor M, Paul J, Plater C, Pare G, Worster A, Varenbut M, Daiter J, Marsh DC, Desai D, Samaan Z, Thabane L.

Trials. 2015 Oct 21;16:475. doi: 10.1186/s13063-015-0942-4. Review.

4.

Impact of Chronic Pain on Treatment Prognosis for Patients with Opioid Use Disorder: A Systematic Review and Meta-analysis.

Dennis BB, Bawor M, Naji L, Chan CK, Varenbut J, Paul J, Varenbut M, Daiter J, Plater C, Pare G, Marsh DC, Worster A, Desai D, Thabane L, Samaan Z.

Subst Abuse. 2015 Sep 10;9:59-80. doi: 10.4137/SART.S30120. eCollection 2015. Review.

5.

Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use.

Mitchell SG, Gryczynski J, Schwartz RP, Myers CP, O'Grady KE, Olsen YK, Jaffe JH.

J Psychoactive Drugs. 2015 Apr-Jun;47(2):149-57. doi: 10.1080/02791072.2015.1014948.

6.

Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Greenwald MK, Comer SD, Fiellin DA.

Drug Alcohol Depend. 2014 Nov 1;144:1-11. doi: 10.1016/j.drugalcdep.2014.07.035. Epub 2014 Aug 19. Review.

7.

Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.

Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, Dossabhoy S, Stein M.

JAMA Intern Med. 2014 Aug;174(8):1369-76. doi: 10.1001/jamainternmed.2014.2556.

8.

Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.

Rosenthal RN, Ling W, Casadonte P, Vocci F, Bailey GL, Kampman K, Patkar A, Chavoustie S, Blasey C, Sigmon S, Beebe KL.

Addiction. 2013 Dec;108(12):2141-9. doi: 10.1111/add.12315. Epub 2013 Sep 18.

9.

Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine.

Edelman EJ, Fiellin DA.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S86-90. doi: 10.1016/j.amepre.2012.09.035. Review. No abstract available.

10.

Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain.

Martinez-Raga J, Gonzalez-Saiz F, Oñate J, Oyagüez I, Sabater E, Casado MA.

Health Econ Rev. 2012 Mar 29;2(1):3. doi: 10.1186/2191-1991-2-3.

11.

Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.

Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA.

J Gen Intern Med. 2012 Jun;27(6):669-76. doi: 10.1007/s11606-011-1962-8. Epub 2012 Jan 4.

12.

Comparison of buprenorphine treatment for opioid dependence in 3 settings.

Miotto K, Hillhouse M, Donovick R, Cunningham-Rathner J, Charuvastra C, Torrington M, Esagoff AE, Ling W.

J Addict Med. 2012 Mar;6(1):68-76. doi: 10.1097/ADM.0b013e318233d621.

13.

Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids.

Daniulaityte R, Falck R, Carlson RG.

Drug Alcohol Depend. 2012 May 1;122(3):201-7. doi: 10.1016/j.drugalcdep.2011.09.029. Epub 2011 Oct 28.

14.

A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.

Rieckmann TR, Kovas AE, McFarland BH, Abraham AJ.

J Subst Abuse Treat. 2011 Dec;41(4):374-85. doi: 10.1016/j.jsat.2011.05.005. Epub 2011 Aug 6.

15.

HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.

Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S22-32. doi: 10.1097/QAI.0b013e318209751e.

16.

A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions.

Cunningham CO, Giovanniello A, Li X, Kunins HV, Roose RJ, Sohler NL.

J Subst Abuse Treat. 2011 Jun;40(4):349-56. doi: 10.1016/j.jsat.2010.12.002. Epub 2011 Feb 18.

17.

Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.

Strain EC, Harrison JA, Bigelow GE.

Clin Pharmacol Ther. 2011 Mar;89(3):443-9. doi: 10.1038/clpt.2010.352. Epub 2011 Jan 26.

18.

Adoption of medications in substance abuse treatment: priorities and strategies of single state authorities.

Rieckmann T, Kovas AE, Rutkowski BA.

J Psychoactive Drugs. 2010 Sep;Suppl 6:227-38.

19.

Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.

Comer SD, Bickel WK, Yi R, de Wit H, Higgins ST, Wenger GR, Johanson CE, Kreek MJ.

Behav Pharmacol. 2010 Jul;21(4):251-77. doi: 10.1097/FBP.0b013e32833bb9f8.

20.

The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence.

Sullivan LE, Moore BA, O'Connor PG, Barry DT, Chawarski MC, Schottenfeld RS, Fiellin DA.

Am J Addict. 2010 Jan-Feb;19(1):53-8. doi: 10.1111/j.1521-0391.2009.00003.x.

Supplemental Content

Support Center